KEI and T1International comments on the prospective grant of an exclusive license to Inversago Pharma, Inc

On August 20, 2018, KEI and T1International filed comments to the NIH regarding the prospective grant of an exclusive license to Inversago Pharma, a firm headquartered in Canada. According to the Federal Register notice 83 FR 38707, the NIH exclusive… Continue Reading

KEI and UACT comments on the prospective grant of an exclusive license to Midissia Therapeutics

Below are the comments filed by Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) regarding a prospective grant of an exclusive license of NIH-owned patents to the California-based company Midissia Therapeutics. The prospective exclusive license is… Continue Reading

16 groups write open letter to WHO Director-General Dr Tedros: Roadmap on Access to Medicines and Vaccines 2019-2023

On Friday, 3 August 2018, 16 groups sent an open letter to WHO Director-General, Dr Tedros Adhanom Ghebreyesus expressing views on the proposed WHO Roadmap on Access to Medicines and Vaccines 2019-2023. The letter requested the Director-General to strengthen activities… Continue Reading

60 House Democrats introduce bill on Medicare negotiations that includes compulsory licensing provisions to protect patients when price negotiations break down.

The new House democrats medicare negotiations bill represents a turning point, with broad support for using robust compulsory licensing authority to protect access if negotiations on prices break down. The press conference announcing the bill featured several Democratic members of… Continue Reading

As Pandemic Preparedness bill clears House committee, effort to include antibiotics transferable exclusivity extension fails

On July 18, 2018, the U.S. House Energy and Commerce committee gave its approval to HR 6378, the Pandemic and All-Hazards Preparedness Act, known as PAHPA. During the mark up, Reps. John Shimkus (R-IL) and Tony Cárdenas (D-CA) proposed attaching… Continue Reading

2018: NIH licenses on Anti-Mesothelin CAR to Atara Biotherapeutics

Attached are comments from 8 health and fair groups regarding a prospective grant of an exclusive license to NIH owned patent, for the development of an Anti-Mesothelin Chimeric Antigen Receptor (CAR) for the treatment of human Cancer, to Atara Biotherapeutics… Continue Reading